Canaccord’s Neil Maruoka jumps up his price target on VRX, but even with more optimism, still angles for 5% downside potential from the stock.
Salix Pharmaceuticals, a wholly owned subsidiary of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), announced today that the U.S.
Goldman Sachs’ Dana Flanders sheds new insights on Valeant from a bearish standpoint, spotting 5% in loss potential for the stock.
Cantor’s Louise Chen dismisses Valeant share weakness today, making a bullish case that the majority of Xifaxan’s sales stem from IBS-D; not Traveler’s Diarrhea.
BTIG’s Tim Chiang notes that with various positives soaring in Valeant’s favor, these are mostly reflected in the stock’s recently climbing levels.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced this morning that its subsidiary Bausch + Lomb has received CE Mark from the European Commission for the …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and its team are raring to continue the rebounding recovery of the once beleaguered biotech giant, and for …
Cantor’s Louise Chen believes Valeant will surpass $8 billion in sales in 2018, and says the set-up for the rebounding giant “keeps getting better” following Lumify’s approval.